Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1978 Oct;64(2):201–209. doi: 10.1111/j.1476-5381.1978.tb17290.x

The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.

J F Deakin, A R Green
PMCID: PMC1668312  PMID: 708990

Abstract

1 The putative 5-hydroxytryptamine (5-HT) receptor blocking drugs methysergide (10 mg/kg) and methergoline (5 mg/kg) were found to abolish some components of the hyperactivity syndrome, including head weaving and forepaw treading, which follow administration to rats of tranylcypromine (20 mg/kg) and L-tryptophan (100 mg/kg). Hyperactivity and hyper-reactivity were potentiated with a resultant increase in automated locomotor activity counts. In contrast (-)-propranolol (20 mg/kg) inhibited all features of the syndrome. The same results were obtained with these drugs when the behaviour was elicited by p-chloroamphetamine (10 mg/kg) or by tranylcypromine and tryptamine (10 mg/kg). 2 Methysergide and methergoline had similar effects on the syndrome produced by tranylcypromine and L-DOPA (50 mg/kg) whereas propranolol was without effect. 3 None of the putative 5-HT receptor antagonists affected brain 5-HT turnover as assessed by rate of accumulation of 5-HT following monoamine oxidase inhibition with tranylcypromine. 4 Microinjections of 5,7-dihydroxytryptamine into the spinal cord resulted in a 70% fall in cord 5-HT concentrations without an effect on brain 5-HT concentrations. The behavioural response to the putative 5-HT receptor agonist, 5-methoxy N,N-dimethyltryptamine (2 mg/kg), was potentiated in these animals suggesting that 5-HT receptors become supersensitive on denervation, and that some components of the behavioural syndrome are mediated by spinal cord 5-HT receptors. 5 Pretreatment with alpha-methyl p-tyrosine (2 X 200 mg/kg) delayed the onset of all components of the behaviour elicited by tranylcypromine/L-tryptophan by 60 min, indicating an involvement of catecholamines in the syndrome. 6 p-Chloroamphetamine-induced 5-HT depletion had no effect on any component of the tranylcypromine-L-DOPA behaviour.

Full text

PDF
201

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banna N. R., Anderson E. G. The effects of 5-hydroxytryptamine antagonists on spinal neuronal activity. J Pharmacol Exp Ther. 1968 Aug;162(2):319–325. [PubMed] [Google Scholar]
  2. Crow T. J., Deakin J. F. Role of tryptaminergic mechanisms in the elements of the behavioural syndrome evoked by tryptophan and a monoamine oxidase inhibitor [proceedings]. Br J Pharmacol. 1977 Mar;59(3):461P–461P. [PMC free article] [PubMed] [Google Scholar]
  3. Curzon G., Green A. R. Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol. 1970 Jul;39(3):653–655. doi: 10.1111/j.1476-5381.1970.tb10373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor. Nature. 1977 May 19;267(5608):289–290. doi: 10.1038/267289a0. [DOI] [PubMed] [Google Scholar]
  5. Enjalbert A., Hamon M., Bourgoin S., Bockaert J. Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system. II. Comparison with dopamine- and isoproterenol-sensitive adenylate cyclases in rat brain. Mol Pharmacol. 1978 Jan;14(1):11–23. [PubMed] [Google Scholar]
  6. Ferrini R., Glässer A. Antagonism of central effects of tryptamine and 5-hydroxytryptophan by 1,6-dimethyl-8beta-carbobenzyloxy-aminomethyl-10alpha-ergoline. Interference with amphetamine and DOPA. Psychopharmacologia. 1965 Nov 16;8(4):271–276. doi: 10.1007/BF00407859. [DOI] [PubMed] [Google Scholar]
  7. Foldes A., Costa E. Relationship of brain monoamine and locomotor activity in rats. Biochem Pharmacol. 1975 Sep 1;24(17):1617–1621. doi: 10.1016/0006-2952(75)90089-1. [DOI] [PubMed] [Google Scholar]
  8. Frey H. H., Magnussen M. P. Different central mediation of the stimulant effects of amphetamine and its p-chloro analogue. Biochem Pharmacol. 1968 Jul;17(7):1299–1307. doi: 10.1016/0006-2952(68)90067-1. [DOI] [PubMed] [Google Scholar]
  9. Grahame-Smith D. G. Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol. 1971 Dec;43(4):856–864. doi: 10.1111/j.1476-5381.1971.tb07222.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grahame-Smith D. G. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem. 1971 Jun;18(6):1053–1066. doi: 10.1111/j.1471-4159.1971.tb12034.x. [DOI] [PubMed] [Google Scholar]
  11. Green A. R., Grahame-Smith D. G. (-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature. 1976 Aug 12;262(5569):594–596. doi: 10.1038/262594a0. [DOI] [PubMed] [Google Scholar]
  12. Green A. R., Grahame-Smith D. G. Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature. 1976 Apr 8;260(5551):487–491. doi: 10.1038/260487a0. [DOI] [PubMed] [Google Scholar]
  13. Green A. R., Grahame-Smith D. G. The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology. 1974 Nov;13(10-11):949–959. doi: 10.1016/0028-3908(74)90086-0. [DOI] [PubMed] [Google Scholar]
  14. Green A. R., Kelly P. H. Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA. Br J Pharmacol. 1976 May;57(1):141–147. doi: 10.1111/j.1476-5381.1976.tb07664.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. HESS S. M., DOEPFNER W. Behavioral effects and brain amine content in rats. Arch Int Pharmacodyn Ther. 1961 Nov 1;134:89–99. [PubMed] [Google Scholar]
  16. Haigler H. J., Aghajanian G. K. Serotonin receptors in the brain. Fed Proc. 1977 Jul;36(8):2159–2164. [PubMed] [Google Scholar]
  17. Hole K., Fuxe K., Jonsson G. Behavioral effects of 5, 7-dihydroxytryptamine lesions of ascending 5-hydroxytryptamine pathways. Brain Res. 1976 May 7;107(2):385–399. doi: 10.1016/0006-8993(76)90235-3. [DOI] [PubMed] [Google Scholar]
  18. Jacobs B. L. An animal behavior model for studying central serotonergic synapses. Life Sci. 1976 Sep 15;19(6):777–785. doi: 10.1016/0024-3205(76)90303-9. [DOI] [PubMed] [Google Scholar]
  19. Jacobs B. L. Evidence for the functional interaction of two central neurotransmitters. Psychopharmacologia. 1974;39(1):81–86. doi: 10.1007/BF00421461. [DOI] [PubMed] [Google Scholar]
  20. Jacobs B. L., Klemfuss H. Brain stem and spinal cord mediation of a serotonergic behavioral syndrome. Brain Res. 1975 Dec 19;100(2):450–457. doi: 10.1016/0006-8993(75)90500-4. [DOI] [PubMed] [Google Scholar]
  21. Neff N. H., Tozer T. N. In vivo measurement of brain serotonin turnover. Adv Pharmacol. 1968;6(Pt A):97–109. doi: 10.1016/s1054-3589(08)61160-6. [DOI] [PubMed] [Google Scholar]
  22. Trulson M. E., Eubanks E. E., Jacobs B. L. Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J Pharmacol Exp Ther. 1976 Jul;198(1):23–32. [PubMed] [Google Scholar]
  23. Weinstock M., Weiss C., Gitter S. Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenoceptor antagonists. Neuropharmacology. 1977 Apr;16(4):273–276. doi: 10.1016/0028-3908(77)90106-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES